Table 2.
Donor | Patient | Pre Transplant Bone Marrow | Pre Transplant Treatment |
2 years Post Transplant Bone Marrow | ||||
---|---|---|---|---|---|---|---|---|
Diagnosis | Cytogenetics | Cellularity** | Diagnosis | Cytogenetics | Cellularity** | |||
MRD | ||||||||
1 | RCMD | Normal | Hypocellular | None | Trilineage hematopoiesis |
46, XY | Normocellular | |
2 | RCMD | N/A | Hypocellular | None | ND | ND | ND | |
3 | RCMD | Trisomy 1q | Hypocellular Gr 1–2 Fibrosis |
None | Trilineage hematopoiesis |
46, XY | Hypocellular Gr 1 Fibrosis |
|
4 | RCMD | Trisomy 8 | Hypocellular Gr 1–2 Fibrosis |
None | Trilineage hematopoiesis |
46, XX | Hypocellular Gr 1–2 Fibrosis |
|
URD | ||||||||
5 | RCMD | -Y | Hypocellular Gr 2 Fibrosis |
None |
*Trilineage hematopoiesis |
46, XX | Normocellular Gr 2 Fibrosis |
|
6 | RCMD | Trisomy 8 | Hypocellular Gr 1–2 Fibrosis |
None | Trilineage hematopoiesis |
46. XX | Hypocellular Gr 1–2 Fibrosis |
|
7 | RAEB1 | Monosomy 7 | Hypercellular | 3+7 | Trilineage hematopoiesis |
46, XX | Normocellular Gr 1 Fibrosis |
|
RCMD | Trisomy 8 | Hypocellular | None | ND | ND | ND | ||
UC | ||||||||
9 | RAEB2 | Monosomy 6, +r | Normocellular Gr 3 Fibrosis |
3+7 | Trilineage hematopoiesis |
46, XY | Hypocellular Gr 3–4 Fibrosis |
|
10 | RCMD | Monosomy 7 | Hypocellular | None | Trilineage hematopoiesis |
46, XY | Hypocellular | |
11 | RCMD | Monosomy 7, Trisomy 21 |
Hypocellular Gr 2 Fibrosis |
None | ND | ND | ND | |
12 | RCMD | Monosomy 6 | Hypocellular Gr 2 Fibrosis |
None | ND | ND | ND | |
Haplo | ||||||||
13 | CMML | Monosomy −7q Trisomy 8 |
Hypercellular Gr 2 Fibrosis |
HIDAC, Melphalan |
ND | ND | ND | |
14 | HLH, EBV (+) T cell LPD |
Normal | Hypocellular | Alemtuzumab,et oposide (HLH) |
*Trilineage hematopoiesis, no EBV detected |
N/A | Hypocellular |
Abbreviations: RAEB: Refractory Anemia with Excess Blasts; LPD: lymphoproliferative disorder; N/A: not available; ND: Not done as patient died prior to 2 years.
Results of last available marrow. Patient 5 refused bone marrow biopsies as of 6 months post transplant. Patient 9 is only 9 months post transplant.
Cellularity for age (100% - age +/− 10%)